Physician

Infectious Disease

Dr. Paula C. Schuman practices Infectious Disease. She graduated from George Washington University School of Medicine. George Washington University School of Medicine has a rank of 67 in research and a 0 in primary care Paula C. Schuman has written publications. She has 52 publications published with PubMed. The lastest paper is: 'Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiologic Research Study Group.'

Publications

---

• The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology.
• Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study.
• Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection.
• Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIV.
• Priorities for antiretroviral therapy research in sub-Saharan Africa: a 2002 consensus conference in Zambia.
• Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women.
• A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use.
• Antiretroviral regimen complexity, self-reported adherence, and HIV patients'' understanding of their regimens: survey of women in the her study.
• Sexual behavior of HIV-infected women reporting recent sexual contact with women.
• The effect of immunodeficiency on cutaneous delayed-type hypersensitivity testing in HIV-infected women without anergy: implications for tuberculin testing. HER Study ...
• Sexual practices in a cohort of US women with and without human immunodeficiency virus. HERS Study. HIV Epidemiology Research Study.
• Comparison of clinical manifestations of HIV infection among women by risk group, CD4+ cell count, and HIV-1 plasma viral load. HER Study Group. HIV Epidemiology Resea...
• Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiologic Research Study Group.
• Multicenter evaluation of hepatitis C RNA levels among female injection drug users.
• Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection.
• Perceived need for and use of mental health services by women living with or at risk of human immunodeficiency virus infection.
• Prevalence of and risk factors for viral infections among human immunodeficiency virus (HIV)-infected and high-risk HIV-uninfected women.
• Regional variation in CCR5-Delta32 gene distribution among women from the US HIV Epidemiology Research Study (HERS).
• Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high ris...
• Substance use and psychotherapeutic medications: a likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus.
• Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women.
• Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999.
• Cancer incidence in women with or at risk for HIV.
• The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-r...
• Effect of HIV infection on menstrual cycle length.
• Oral lesions among women living with or at risk for HIV infection. HIV Epidemiology Research Study (HERS) Group.
• A multicenter study of bacterial vaginosis in women with or at risk for human immunodeficiency virus infection.
• Effect of HIV infection on atypical squamous cells of undetermined significance.
• The effects of illicit drug use and HIV infection on sex hormone levels in women.
• Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women.
• Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus.
• Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women.
• Highly active antiretroviral therapy associated with improved anemia among HIV-infected women.
• Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study.
• Evaluation of possible effects of continued drug use on HIV progression among women.
• Influence of injection drug use behavior on reported antiretroviral therapy use among women in the HIV Epidemiology Research study: on-site versus referral care.
• Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women.
• Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group.
• Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
• Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemi...
• Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women.
• Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Stud...
• Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women.
• Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV.
• Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
• Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.
• Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care.
• The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts.
• Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy.
• Clinical and immunologic progression in HIV-infected US women before and after the introduction of highly active antiretroviral therapy.
• Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus.

Schools

---

• George Washington University School of Medicine And Health Sciences

• Johns Hopkins Med Institute

Doctors Specialties

---

• Infectious Disease Medicine
• Infectious Disease

Accepted Insurances

---

Education

---

• Johns Hopkins Bayview Medical Center
• George Washington University School of Medicine

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. David M. Rowles, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael B. Edmond, MD This Doctor is OpenDoctor Recommended.
	Dr. Ronald P. Artz, MD This Doctor is OpenDoctor Recommended.
	Dr. Jane A. Cecil, MD This Doctor is OpenDoctor Recommended.
	Dr. Jeffrey M. Tessier, MD This Doctor is OpenDoctor Recommended.
	Dr. Edward S. Wong, MD
	Dr. Richard P. Wenzel, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Diane S. Sinnatamby, MD This Doctor is OpenDoctor Recommended.
	Dr. Vivian L. Bruzzese, MD This Doctor is OpenDoctor Recommended.
	Dr. Suzanne R. Lavoie, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael W. Climo, MD This Doctor is OpenDoctor Recommended.
	Dr. Mark A. Gentz, MD This Doctor is OpenDoctor Recommended.
	Dr. Claudia D. Jarrin Tejada, MD
	Dr. Leroy B. Vaughan Jr., MD
	Dr. Jeffrey S. Wang, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog